Yazarlar : Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DP, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL.

Yayın : Blood.

Yayın Yılı : 2011

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/21937701

Konu : Lenfoma

Literatür İçeriği :

Abstract

Relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) remains a clinical challenge with limited effective treatments after stem cell transplantation. In a multicenter phase 2 study, the efficacy of lenalidomide in rel/ref cHL patients was evaluated at a dose of 25 mg on days 1-21 of a 28-day cycle. Patients remained on lenalidomide until disease progression or an unacceptable adverse event occurred. Thirty-eight cHL patients were enrolled with a median of 4 (range 2-9) prior therapies; 87% had undergone prior stem cell transplantation and 58% of patients did not respond to their last prior therapy. Of 36 evaluable patients, responses were 1 CR, 6 PRs, and 5 patients with SD for ≥ 6 months resulting in an international working committee objective overall response rate (ORR) of 19% and cytostatic ORR of 33%. Decreased chemokine (CCL17 and CCL22) plasma levels at 2 weeks were associated with a subsequent response. The treatment was well tolerated, and the most common grade 3/4 adverse events were neutropenia (47%), anemia (29%), and thrombocytopenia (18%). Four patients discontinued lenalidomide due to rash, elevated transaminases/bilirubin, and cytopenias. Thus, lenalidomide has preliminary evidence of activity in patients with rel/ref cHL, and exploration of lenalidomide in combination with other active agents is warranted. This trial is registered at www.clinicaltrials.gov as NCT00540007.

Literatür Arşivi